Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Lung Cancer

• Publication date

  2015-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.lungcan.2015.01.020PMID 25682925PMCID PMC4355240
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.

  2014cited by this paper
• Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.

  2014influential reference
• Management and future directions in non-small cell lung cancer with known activating mutations.

  2014influential reference
• EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?

  2014cited by this paper
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013cited by this paper
• Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.

  2013cited by this paper
• Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

  2012cited by this paper
• The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012influential reference
• Epidemiology of Brain Metastases

  2012cited by this paper
• CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

  2011cited by this paper
• EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.

  2010cited by this paper
• Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

  2010cited by this paper
• Does Initial Staging or Tumor Histology Better Identify Asymptomatic Brain Metastases in Patients with Non–small Cell Lung Cancer?

  2006cited by this paper
• Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.

  2004cited by this paper
• [Epidemiology of brain metastases].

  1999cited by this paper
• A Proportional Hazards Model for the Subdistribution of a Competing Risk

  1999cited by this paper

• Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study).

  2026cites this paper
• First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?

  2026cites this paper
• First Things First: Navigating ALK-Positive Metastatic Non-Small Cell Lung Cancer Treatment Options-A Podcast.

  2026cites this paper
• Brain metastases from non-small cell lung cancer: molecular subtypes and emerging CNS-directed precision therapies

  2026cites this paper
• Clinicopathological conference: a pregnant woman with headache and migratory sensory symptoms

  2026cites this paper
• Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study.

  2025cites this paper
• Survival outcomes of upfront versus delayed craniocerebral radiotherapy in EGFR-mutant NSCLC patients treated with third-generation EGFR-TKIs

  2025cites this paper
• A clinical model to predict brain metastases in resected early-stage non-small cell lung cancer

  2025cites this paper
• Mechanisms of Resistance to ALK Inhibitors and Corresponding Treatment Strategies in Lung Cancer

  2025cites this paper
• New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era.

  2025cites this paper
• Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC.

  2025cites this paper
• Dacomitinib in the treatment of EGFR-mutated non-small cell lung cancer with brain metastases: an open-label, multicenter, phase II study.

  2025cites this paper
• Central Nervous System Outcomes of Lazertinib Treatment in EGFR-Mutated Advanced NSCLC: Pooled Analysis From LASER201 and LASER301.

  2025cites this paper
• Cerebrospinal fluid circulating tumor DNA profiling for risk stratification and matched treatment of central nervous system metastases

  2025cites this paper
• Targeted Drug Selection in Non-Small Cell Lung Cancer Patients with EGFR Mutation-Induced Brain Metastases

  2025cites this paper
• Roles of the WNT/β-catenin signaling pathway in the metastasis and recurrence of NSCLC

  2025cites this paper
• First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases.

  2025cites this paper
• Analysis of prognostic factors influencing brain metastasis in EGFR-mutant lung adenocarcinoma and comparison of prognostic assessment models

  2025cites this paper
• Lung adenocarcinoma harboring uncommon EGFR exon 19 deletion L747_T751del and in cis K754E mutation: a case report and literature review

  2025cites this paper
• Surgical and Perioperative Advances for Patients With Locally Advanced Non-Small Cell Lung Cancer.

  2025cites this paper
• The curse of blood–brain barrier and blood–tumor barrier in malignant brain tumor treatment

  2025influential citation
• Efficacy analysis of brain radiotherapy in EGFR mutation non-small cell lung cancer with brain metastasis: a retrospective study

  2025cites this paper
• FLAURA2: evidence for escalated first-line therapy in EGFR-mutated non-small cell lung cancer with central nervous system metastases

  2025cites this paper
• Identifying the genomic landscape of EGFR-mutant lung cancers with CNS metastases.

  2025cites this paper
• Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts.

  2025cites this paper
• Surgical consensus for screening, diagnosis, staging, multimodal management and surveillance of early-stage resectable non-small cell lung cancer (NSCLC) in Malaysia

  2025cites this paper
• Single Pontine Relapse Shortly After Hippocampal Avoidance Whole Brain Radiotherapy: A Case Report

  2025cites this paper
• AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions

  2025cites this paper
• Expanding Lung Cancer Clinical Trial Criteria: A Systematic Review on Inclusion of Patients with Brain Metastases and Leptomeningeal Disease.

  2025cites this paper
• Chromosome 15q15 Deletion Drives Brain Metastasis in Non-Small Cell Lung Cancer.

  2025cites this paper
• Phase 2 study of amivantamab plus lazertinib in previously-treated patients with EGFR mutant lung cancers with brain and leptomeningeal metastases.

  2025cites this paper
• Clinical Pharmacokinetic Assessment of Lazertinib in Healthy Adult Participants: Effects of GSTM1 Genotype

  2025cites this paper
• Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation.

  2025cites this paper
• New therapies for brain metastases: an update.

  2025cites this paper
• Molecular Underpinnings of Brain Metastases

  2025cites this paper
• Evolution of first versus next-line targeted therapies for metastatic non-small cell lung cancer.

  2025cites this paper
• Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy—let’s define who benefits the most

  2025cites this paper
• Long-Term Safety and Management of Adverse Events Associated With Lorlatinib in ALK-Positive Metastatic NSCLC: A Fictional Case Study.

  2025cites this paper
• Early predicting brain metastases of EGFR positive lung adenocarcinoma patients by CT radiomics.

  2025cites this paper
• Given TKIs With High CNS Penetrance, Systemic Therapy Should Be Administered Before Radiation Therapy for CNS Metastases.

  2025cites this paper
• Prediction of brain metastasis in patients with epidermal growth factor receptor-positive lung adenocarcinoma based on lung computed tomography-derived radiomics features

  2025cites this paper
• Deep learning radiomics for the prediction of epidermal growth factor receptor mutation status based on MRI in brain metastasis from lung adenocarcinoma patients

  2025cites this paper
• Efficacy and Safety of EGFR-TKI Combined With Early Brain Radiotherapy Versus TKI Alone in Patients With EGFR-Mutated NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis.

  2025cites this paper
• The effect of radiotherapy on patients with EGFR-driven lung cancer brain metastasis: a systematic review and meta-analysis

  2025cites this paper
• Cost-Effectiveness of Adjuvant Alectinib Versus Chemotherapy for Patients with Resectable, ALK-positive Non-small Cell Lung Cancer in Canada

  2025cites this paper
• Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: a multicenter cohort study

  2025cites this paper
• Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.

  2025cites this paper
• Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases.

  2025cites this paper
• Therapeutic Outcomes of Osimertinib in EGFR – Mutant Non-Small Cell Lung Cancer With Brain Metastases: Results From a Retrospective Study at Vietnam National Cancer Hospital

  2025cites this paper
• Local cranial radiation combined with third-generation tyrosine kinase inhibitors improve leptomeningeal metastasis disease-free survival in patients with EGFR-mutated non-small cell lung cancer and brain metastasis

  2025cites this paper
• Predicting brain metastases in EGFR-positive lung adenocarcinoma patients using pre-treatment CT lung imaging data.

  2025cites this paper
• Survival Outcomes in Lung Cancer Patients Newly Diagnosed Through Brain Metastasis Surgery: Impact of Druggable Mutations and Radiotherapy

  2025influential citation
• Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China

  2025influential citation
• Serum sphingosine-1-phosphate levels are associated with brain metastasis in EGFR-mutant lung adenocarcinoma.

  2025cites this paper
• Molecular and clonal evolution of primary lesions vs. brain metastasis in EGFR-mutated NSCLC: a retrospective cohort study

  2025cites this paper
• Management of Central Nervous System Progression With Dose-Escalated Lorlatinib in ALK-Positive NSCLC: A Report of 2 Cases and Literature Review.

  2025cites this paper
• What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review

  2025cites this paper
• Cost-effectiveness analysis of first-line gifitinib plus pemetrexed-platinum-based chemotherapy versus gifitinib monotherapy in EGFR-mutated NSCLC patients with brain metastases

  2025cites this paper
• BBB-penetrant tyrosine kinase inhibitor plus intracranial radiotherapy vs BBB-penetrant TKI alone in Asians with EGFR-mutated lung adenocarcinoma and brain metastases

  2025cites this paper
• Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors.

  2025cites this paper
• Lorlatinib Induced Non-cardiogenic Pulmonary Edema

  2025cites this paper
• Genomic Signature for Initial Brain Metastasis Velocity (iBMV) in Non-Small-Cell Lung Cancer Patients: The Elusive Biomarker to Predict the Development of Brain Metastases?

  2025cites this paper
• Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study.

  2025cites this paper
• Immunotherapy in lung cancer brain metastases

  2025cites this paper
• A Nomogram for Predicting Survival for Patients with Brain Metastatic and EGFR Mutation Advanced Non-Small Cell Lung Cancer

  2025cites this paper
• Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).

  2025cites this paper
• Patient-derived organoid facilitating personalized medicine in non-small cell lung cancer: two case reports

  2025cites this paper
• Can radiomics in brain magnetic resonance imaging predict the mutational status of primary lung cancer based on brain metastasis?

  2025cites this paper
• Discovery of a brain-penetrant fourth-generation EGFR inhibitor to overcome the human triple (L858R/T790 M/C797S) mutation.

  2025cites this paper
• Lung cancer In non-smokers

  2025cites this paper
• Breaking boundaries: role of the brain barriers in metastatic process

  2025cites this paper
• Based on the CROWN Findings, Lorlatinib Should Be the Preferred First-Line Treatment for Patients With Advanced ALK-Positive NSCLC.

  2025cites this paper
• Long term efficacy and safety of Lorlatinib in ALK-positive Non-small Cell Lung Cancer: a case report

  2025cites this paper
• Divergent Crosstalk Between Microglia and T Cells in Brain Cancers: Implications for Novel Therapeutic Strategies

  2025cites this paper
• Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta

  2024cites this paper
• Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial.

  2024cites this paper
• Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape.

  2024cites this paper
• Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK+ non‐small cell lung cancer using South Korean claims data (K‐AREAL)

  2024cites this paper
• Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer

  2024cites this paper
• Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)

  2024cites this paper
• Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors

  2024cites this paper
• TP53 and EGFR amplification are negative predictors of overall survival in patients diagnosed with non-small cell lung cancer with brain metastases

  2024influential citation
• Population pharmacokinetics and exposure–response analyses of SAF-189s in Chinese patients with ALK+/ROS1+ non-small cell lung cancer

  2024cites this paper
• Enhancing intracranial efficacy prediction of osimertinib in non-small cell lung cancer: a novel approach through brain MRI radiomics

  2024cites this paper
• Correction: Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer

  2024cites this paper
• Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK-Positive Non-small Cell Lung Cancer.

  2024cites this paper
• Double-dose osimertinib combined with intrathecal injection of pemetrexed improves the efficacy of EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis: case report and literature review

  2024cites this paper
• Prediction of epidermal growth factor receptor mutation subtypes in non-small cell lung cancer from hematoxylin and eosin-stained slides using deep learning.

  2024cites this paper
• Targeted therapeutic options in early and metastatic NSCLC-overview

  2024cites this paper
• New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors.

  2024cites this paper
• A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases

  2024cites this paper
• Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.

  2024cites this paper
• Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings

  2024cites this paper
• Brain Metastasis from EGFR‐Mutated Non‐Small Cell Lung Cancer: Secretion of IL11 from Astrocytes Up‐Regulates PDL1 and Promotes Immune Escape

  2024cites this paper
• Anti-EGFR ScFv functionalized exosomes delivering LPCAT1 specific siRNAs for inhibition of lung cancer brain metastases

  2024cites this paper
• Surgery of enlarging lesions after stereotactic radiosurgery for brain metastases in patients with non‐small cell lung cancer with oncogenic driver mutations frequently reveals radiation necrosis: case series and review

  2024cites this paper
• Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

  2024cites this paper
• Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy

  2024cites this paper
• Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC

  2024cites this paper
• Oncogenic alterations in advanced NSCLC: a molecular super-highway

  2024cites this paper